Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Kenji Hirotani, Martin Forster, Shuquan Chen, Christophe Le Tourneau, Jonathan Greenberg, Jose Ariza, Éva Remenár, Kevin J. Harrington
Publikováno v:
Journal of Clinical Oncology. 36:6045-6045
6045Background: P, a fully human monoclonal antibody can block HER3 activation. HER3 activation is a resistance mechanism to C, induced by the ligand heregulin (HRG). This randomized phase 2 study ...
Autor:
Justin Kopit, Lisa Licitra, Mark Lynch, Joël Guigay, A. Dimitrios Colevas, Jérôme Fayette, Tamara Rordorf, Makoto Tahara, Nabil F. Saba, Lara Carmen Iglesias Docampo, Kevin J. Harrington, Maura L. Gillison, Robert I. Haddad, Stefan Kasper, Naomi Kiyota, Francis P. Worden, George R. Blumenschein, Robert L. Ferris, Caroline Even, Everett E. Vokes
Publikováno v:
Journal of Clinical Oncology. 35:6019-6019
6019 Background: In CheckMate 141, a randomized, phase 3 trial, nivo demonstrated superior overall survival (OS) and better tolerability in patients (pts) with PR R/M SCCHN compared with IC. Pts with SCCHN progressing within 6 mos of platinum in the
Autor:
Maura L. Gillison, Nabil F. Saba, Caroline Even, Peter Brossart, George R. Blumenschein, Lisa Licitra, Joël Guigay, Jérôme Fayette, Jeffrey Russell, Robert I. Haddad, Robert L. Ferris, Kevin J. Harrington, Shanmugasundaram Ramkumar, Jin Zhu, Manish Monga, Makoto Tahara, A. Dimitrios Colevas, Everett E. Vokes
Publikováno v:
Journal of Clinical Oncology. 35:6020-6020
6020 Background: In CheckMate 141, nivo resulted in significantly prolonged overall survival (OS), favorable safety, and stable quality of life vs IC in patients (pts) with platinum-refractory (PR) R/M SCCHN. Cetuximab, a formal trial stratification
Autor:
Kevin J. Harrington, Jonathan Greenberg, Kandance Cooper, Henrik Hannus, Sola Adeleke, Shuquan Chen, Jane S. Diamond, Martin Forster, Lorna Grove, Magnus T. Dillon
Publikováno v:
Journal of Clinical Oncology. 34:TPS6104-TPS6104
TPS6104Background: P is a fully human monoclonal antibody against human epidermal growth factor receptor 3. P blocks activation by the ligand, heregulin (HRG), inducing receptor internalization. Ev...